Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing

Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing Whose Maturation Depends on the Protein HuR, Including Gene Encoding Insulin Receptor

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01349387

Acronym

METFORGENE

Enrollment

Registered

2011-05-06

Start date

2011-05-31

Completion date

2012-01-31

Last updated

2012-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Main objective : Show that treatment with metformin in patients with type 2 diabetes has an effect on alternative splicing of the insulin receptor. Secondary objective : demonstrate that the effect on the ratio A/isoform B isoform with discontinuation of treatment with metformin can be réversé by the resumption of metformin treatment.

Interventions

DRUGMetformin

After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Type 2 Diabetic patients usually treated with metformin (≥ 1400 mg/day), associated or not to other oral anti-diabetic treatment or. injection treatment * Patients major. * Patients with a social security number * Patients having signed a consent to participate in the study

Exclusion criteria

* Intolerance metformin * Patients with type 1. * Patients on pioglitazone or rosiglitazone * Renal failure by an anomaly of the creatinine clearance (\< 60 mL/min). * Patients pregnant or likely to be.

Design outcomes

Primary

Measure	Time frame	Description
Comparison of expression of isoforms A and B of the insulin receptor using quantitative RT PCR	inclusion (baseline), 30th days and 60th days	comparison of the A isoform (without inclusion of exon 11) and B isoform (with inclusion of exon 11) ratio of the receptor in insulin, during the first period (without metformin) and the second period (with metformin)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026